List of Ixempra Kit drug patents

Ixempra Kit is owned by R-Pharm Us Llc.

Ixempra Kit contains Ixabepilone.

Ixempra Kit has a total of 8 drug patents out of which 6 drug patents have expired.

Expired drug patents of Ixempra Kit are:

  • US7022330
  • US6670384
  • USRE41393
  • US6670384*PED
  • US7022330*PED
  • USRE41393*PED

Ixempra Kit was authorised for market use on 16 October, 2007.

Ixempra Kit is available in injectable;intravenous dosage forms.

Ixempra Kit can be used as method of treating breast cancer by administering ixabepilone; a method of treating a cancer responsible to microtubule stabilization by administering ixabepilone, use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer, method of treating patient comprising mixing first and second vials of product comprising lyophilized ixabepilone to provide an epothilone analog solution, diluting solution with a suitable diluent to prepare intravenous formulation for pt, method of treating cancer in a patient comprising intravenously administering to the patient ixabepilone diluted in a parenteral diluent; method of treating cancer, iv admin, lyophilized ixabepilone diluted, every week or 3 weeks; lyophilized ixabepilone with solvent(dehydrated ethanol) diluted to concentration of 0.1mg/ml to 0.9mg/ml.

The generics of Ixempra Kit are possible to be released after 21 February, 2025.

IXEMPRA KIT Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7022330 R-PHARM US LLC Parenteral formulation for epothilone analogs
Jan, 2022

(1 year, 1 month ago)

US6670384 R-PHARM US LLC Methods of administering epothilone analogs for the treatment of cancer
Jan, 2022

(1 year, 1 month ago)

USRE41393 R-PHARM US LLC Treatment of refractory tumors using epothilone derivatives
Feb, 2022

(1 year, 1 month ago)

US6670384

(Pediatric)

R-PHARM US LLC Methods of administering epothilone analogs for the treatment of cancer
Jul, 2022

(7 months ago)

US7022330

(Pediatric)

R-PHARM US LLC Parenteral formulation for epothilone analogs
Jul, 2022

(7 months ago)

USRE41393

(Pediatric)

R-PHARM US LLC Treatment of refractory tumors using epothilone derivatives
Aug, 2022

(7 months ago)

US7312237 R-PHARM US LLC Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
Aug, 2024

(1 year, 5 months from now)

US7312237

(Pediatric)

R-PHARM US LLC Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
Feb, 2025

(1 year, 11 months from now)

Drugs and Companies using IXABEPILONE ingredient

Market Authorisation Date: 16 October, 2007

Treatment: Method of treating patient comprising mixing first and second vials of product comprising lyophilized ixabepilone to provide an epothilone analog solution, diluting solution with a suitable diluent to prepare intravenous formulation for pt; Method of treating cancer in a patient comprising intravenously administering to the patient ixabepilone diluted in a parenteral diluent; Method of treating cancer, iv admin, lyophilized ixabepilone diluted, every week or 3 weeks; Lyophilized ixabepilone with solvent(dehydrated ethanol) diluted to concentration of 0.1mg/ml to 0.9mg/ml; Method of treating breast cancer by administering ixabepilone; A method of treating a cancer responsible to microtubule stabilization by administering ixabepilone; Use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of IXEMPRA KIT before it's patent expiration?
More Information on Dosage

IXEMPRA KIT family patents

25

United States

5

Norway

5

China

5

Canada

5

European Union

4

Russia

4

Brazil

4

Estonia

4

Mexico

4

Argentina

4

Korea, Republic of

4

South Africa

4

Slovakia

4

Japan

4

Bulgaria

4

Hungary

4

Czech Republic

4

Iceland

4

Poland

3

Uruguay

3

Croatia

3

Peru

3

Taiwan, Province of China

3

Hong Kong

3

Yugoslavia

3

Australia

2

Spain

2

New Zealand

2

Austria

1

Portugal

1

Germany

1

Cyprus

1

Slovenia

1

Israel

1

Denmark

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in